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In order to understand more clearly the epidemiology of nerve
function impairment (NFI) and its incidence, risk factors, and
response to treatment, a prospective cohort study has been
initiated at the Danish Bangladesh Leprosy Mission (DBLM).
The design, methodology, and intake status have been described
in an earlier paper.1 The incidence rates of acute NFI after a
follow-up period of 24 months in this cohort of 2664 newly
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Background Nerve function impairment (NFI) is the key outcome of the pathological
processes of infection with Mycobacterium leprae, which can continue after
completion of multidrug therapy (MDT) and lead to disability after leprosy
patients are released from treatment. The objective of this study was to assess the
need for and duration of surveillance of NFI.
Methods Prospective cohort study of 2664 new leprosy patients in Bangladesh, with an
observation period of 36 months in paucibacillary (PB) patients, and 60 months
in multibacillary (MB) patients. Incidence rates (IR) were calculated with the
number of patients developing NFI, type 1 and type 2 reactions, and silent
neuritis for the first time after registration as the numerator, and cumulative
person-years at risk (PYAR) as the denominator. Survival curves to the first event
of NFI were also calculated.
Results The IR of first event of NFI amongst MB patients was 16.1 per 100 PYAR, with
121/357 (34%) developing NFI during the observation period. Of the 121 with a
first event of NFI, 77 (64%) had this within a year after registration, 35 (29%) in
the second year, and the remaining 9 (7%) after 2 years. The IR of first event of
NFI amongst PB patients was 0.9 per 100 PYAR, with 54/2153 (2.5%) developing
NFI during the observation period. Of the 54 with a first event of NFI, 48 (89%)
had this within a year after registration, 3 (5.5%) in the second year, and the
remaining 3 (5.5%) cases after 2 years. The percentage of PB patients with no NFI
at registration surviving without developing NFI during the observation period
was 99% and for PB patients with NFI at registration 92%. In MB patients
without NFI at registration, the percentage surviving with no NFI during the
observation period was 84% and for MB patients with NFI at registration only
36%.
Conclusion New episodes of NFI and reactions after registration are common, in particular in
MB patients with long-standing NFI at registration. The study highlights the
importance of continuing surveillance for NFI of this risk group after registration
for 2 years. Active surveillance beyond 2 years is not indicated.
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diagnosed leprosy patients was described previously.2 Follow-
up of patients included in the cohort continued for up to 3 years
from the time of registration in the case of paucibacillary (PB)
patients, and for up to 5 years for multibacillary (MB) patients.
This paper presents the results at 5 years (60 months) of follow-up.
NFI results from a variety of pathological and immunological
processes taking place in peripheral nerves. These include the
presence of Mycobacterium leprae in the nerve, trauma, oedema
causing increased intraneural pressure, vascular changes, and
hypersensitivity granuloma.3 Reactive states, including type 1
and type 2 reactions, are widely accepted as common causes of
NFI and of these, type 1 or reversal reaction is regarded as the
leading cause.4 However, nerves are often functionally impaired
without developing obvious symptoms such as skin reactions or
nerve pain, and this condition is variously called ‘silent neuri-
tis’,5 ‘silent neuropathy’,6 or ‘quiet nerve paralysis’.7
The majority of patients developing NFI events do so in the
first year after registration.2,8–12 Although the proportion of
patients experiencing their first NFI event diminishes with time,
evaluation of the Bangladesh Acute Nerve Damage Study
(BANDS) cohort at 24 months showed that amongst MB patients
there was a moderate number who had their first episode after
18 months of multidrug therapy (MDT).2 This highlighted the
importance of continuing vigilance after registration for at least
2 years, especially in the case of MB patients. It is known that
NFI and reactions continue after 2 years.11–14 Because of the
need to prevent further disability in leprosy patients after com-
pletion of MDT, it is important to know how often NFI and
leprosy reactions may be expected beyond 2 years after regis-
tration, and which patients are at particular risk.
In this paper, the incidence rates (IR) and cumulative inci-
dence of NFI and other reactive phenomena amongst patients in
the BANDS cohort are presented for the following risk variables:
leprosy group (PB/MB) and presence or absence of NFI at
registration. Survival curves to the first event of NFI during the
60-month observation period have been calculated and are also
presented in the paper.
Materials and Methods
The patient cohort and follow-up
The study group is the BANDS cohort.1 The 2664 patients
recruited over a 12-month period comprise 1481 males (56%)
and 1183 females (44%). In all, 2220 (83%) of the patients were
PB, and 444 (17%) were MB. All patients have been treated
according to WHO guidelines for MDT current at the time of the
study as follows: PB cases: Rifampicin 600 mg supervized dose,
DDS 100 mg daily, total 6 months’ treatment; MB cases:
Rifampicin 600 mg and Clofazimine 300 mg supervized dose,
DDS 100 mg daily and Clofazimine 50 mg daily, total 24 monthly
doses. This dose regimen is used for all normal-sized adults;
lower doses for small adults and children are given according to
the Bangladesh national treatment guidelines. Amongst the PB
group, 14 patients were reclassified as MB during the course of
follow-up, and they were started on MB/MDT. In these patients,
a type 1 reaction (reversal reaction) caused skin patches that had
been invisible at the time of registration to become visible. This
made reclassification of these patients into the MB group
necessary, since classification was based on a count of patches
combined with the number of palpable enlarged nerves and skin
smear results (>10 skin patches and enlarged nerves and/or skin
smear positive = MB). However, since these cases were correctly
diagnosed as PB according to the diagnostic tools available at the
time of registration, they have been considered as PB for the
purposes of analysis. In other words, the initial classification of
PB or MB was ‘fixed’ for subsequent analysis.
Details of follow-up procedures have been described.1 PB
patients have completed at least 36 months, and MB patients at
least 60 months of follow-up after registration. Duration of
follow-up was based on available information at the time of
occurrence of NFI after completion of MDT, which is more
common in MB as compared with PB leprosy. All analysis in this
paper is based on these follow-up periods.
Analysis will focus on the incidence of the first episode of NFI
during follow-up as the main outcome. The definition of NFI
used is as follows:
Sensory nerve function impairment
Reduction by 2 points in the sensory distribution of any one
nerve, as tested by ballpoint pen using the standard test sites
described.1 The following nerves were tested for sensory
function: ulnar, median, and posterior tibial.
Motor nerve function impairment
Reduction by 2 in the MRC grade of the movement tested of
any one nerve as described earlier. The following nerves were
tested for motor function: facial, ulnar, median, radial, and
lateral popliteal.
Full details of testing and other outcome definitions such as
type 1 reaction (reversal reaction), type 2 reaction (erythema
nodosum leprosum [ENL]), and silent neuritis are described in
the earlier paper.1 The testing methods have been validated in a
separate publication.15 In this paper, a patient is said to have
developed an ‘NFI event’ (positive outcome) if he or she has
had either sensory or motor NFI, or both, unless stated
otherwise.
Statistical methods
IR have been calculated using the number of patients
developing a first event of NFI or reactions as the numerator,
and cumulative person-years at risk (PYAR) as the
denominator, expressed as 100 PYAR.
Patients who were lost to follow-up, died, or who were
transferred out of the project were included in the denominator
for as long as follow-up was possible, up to the final assessment
around 36 months in PB, and around 60 months in MB
patients. Patients were discontinued from the denominator as
soon as they developed an event of the type for which the IR
was being calculated (i.e. NFI or reaction).
Survival curves were calculated of the percentage of patients
surviving without a first event of NFI or reaction against time
since registration. The log rank test was carried out to assess 
the significance of differences between the curves at end-point,
and the P-value has been given in the text. The cumulative
incidence at final assessment is given.
Number of at-risk cases used in calculations
The number of at-risk cases (which appears in the denominator
of the incidence calculation, to determine the number of PYAR)
is the total number of patients in the BANDS cohort (2664), less
the number of patients who had an episode of NFI or reaction
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that needed prednisolone treatment at registration (119), less
the number of other patients who received prednisolone treat-
ment at the time of registration for any other reason (e.g. those
who did not strictly fulfil the standard treatment criteria, but
who still received prednisolone) (35), leaving the total number
of patients entering the denominator at the beginning of the
study as 2510.
Risk factors considered for analysis
Two variables have been selected for analysis. They are: leprosy
group (MB/PB) and the presence or absence of long-standing
NFI at registration (i.e. 6 months duration). These two have
been selected because they are fundamental to the assessment
of a leprosy patient at registration, and can be carried out
without difficulty in any control programme. For other basic
variables such as age and sex it has been shown previously
that they are not strong predictors for the occurrence of NFI
during treatment and follow-up.16 Classification into MB and
PB for treatment purposes is usually carried out using either the
WHO method of counting skin patches17 or a similar procedure
such as the Bangladesh system of counting patches and
enlarged nerves,18 in combination with skin smear results.
As already mentioned, all patients with acute NFI/reaction
(6 months duration) needing treatment with prednisolone at
registration have been excluded from analysis, since it is
difficult to be certain of whether a subsequent ‘NFI event’ truly
represents a new episode or a continuation of the first. In
addition, for this group of patients outcome will have been
modulated by having received prednisolone therapy, and
therefore a comparison with patients who did not receive
prednisolone is not possible. However, it was felt important to
consider whether patients who had long-standing NFI at
registration (6 months duration) are at increased risk of
developing another episode.
Results
Status of the cohort at 5 years
Table 1 shows the status of the BANDS cohort patients at 3 years
(PB) and 5 years (MB) from the time of registration. A total of
2076 PB patients (93%) remained under observation for the
complete follow-up period of 36 months and 363 MB patients
(82%) for the complete follow-up period of 60 months. Patients
were considered to be lost to follow-up if their date of expected
contact with DBLM staff was more than 3 months overdue
despite active attempts at tracing. Out of 2220 PB patients, 14
were reclassified as MB during treatment, leaving 2206.
Incidence rates and cumulative incidence of all
nerve function impairment, type 1 and 2 reactions,
and silent nerve function impairment during 
follow-up
Table 2 shows the IR expressed per 100 PYAR of NFI, and the
cumulative incidence at final assessment. Results are shown for
all episodes of NFI, and for type 1 reaction, type 2 reaction, and
silent neuritis separately. A breakdown is also given for any new
event of NFI in patients with and without NFI at registration.
The definition of NFI used strictly follows the definitions given
in the earlier paper.1 For all NFI events, the IR amongst MB
cases of 16.1/100 PYAR compares with 0.85/100 amongst PB
cases. For the risk factor of presence of long-standing NFI at
registration, the IR is even higher at 46.2/100 PYAR compared
with 7.4/100 PYAR amongst those without NFI at registration in
MB patients, and 4.42/100 versus 0.61/100 in PB patients. The
cumulative incidences parallel the IR.
The same statistics for type 1 and 2 reactions, and silent
neuritis are also shown in Table 2. Type 1 reaction as defined for
Table 2 means patients with a skin reaction with or without NFI.
The overall IR for type 1 reactions in MB patients is half of the
rate for NFI, 8.0/100 PYAR compared with 16.1/100 PYAR. In
PB patients this difference in IR is 0.30/100 PYAR compared
with 0.85/100 PYAR. Only eight patients developed a type 2
reaction during follow-up. The overall IR for type 2 reactions in
MB patients is 1.1/100 PYAR compared with 16.1/100 PYAR for
all NFI and 8.0/100 PYAR for type 1 reaction.
The IR and cumulative incidences for patients with silent NFI
(silent neuropathy) are very similar to those for NFI in general,
which is not surprising since the majority of NFI cases were in
fact silent (151/175, 86%). The IR for silent NFI is 13.4/100
PYAR amongst MB patients, and 0.79/100 PYAR amongst PB
patients.
Incidence rates of nerve function impairment during
6- and 12-month blocks of follow-up
Figures 1, 2, and 3 show the IR for development of the first
event of NFI during follow-up. The first year is divided into two
periods of 6 months, while the following years are divided into
periods of 12 months. The numerator is the number of events
occurring during these periods. The denominator is the number
of days at risk for patients continuing in follow-up with no
new outcome events. These IR have been calculated for the diag-
nostic groups PB/MB and include the first event of NFI (Figure 1),
the first event of type 1 reaction (Figure 2), and the first event
of type 2 reaction (Figure 3). For all there is a stepwise
reduction in IR for successive 6-month and 12-month periods.
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Table 1 Status of BANDS cohort patients at 3 years (36 months) for paucibacillary (PB) patients, and at 5 years (60 months) for multibacillary
(MB) patients from registration, according to diagnostic group (MB or PB) and outcome of follow-up. N = 2664
Patients who were Patients who were
classified MB at registration classified PB at registration Total
Status at 60 months N % N % N %
In follow-up 363 82% 2076 93% 2439 92%
Lost to follow-up 44 10% 89 4% 133 5%
Died 27 6% 35 2% 62 2%
Transferred to other project 10 2% 20 1% 30 1%
Total 444 100% 2220 100% 2664 100%
The IR of first event of NFI (Figure 1) amongst MB patients
during the first 6 months after registration is very high at
33.3/100 PYAR, representing 51 events. This figure has halved
to 16.5/100 PYAR (35 events) in the second year of follow-up.
In the third and fourth year the IR stabilizes around 5.5/100
PYAR (8 and 1 event respectively). No new events were
observed in the final year. For the PB group, the IR for the first
event of NFI is much lower, starting with 3.0/100 PYAR 
(32 events) in the first 6 months and 1.5/100 PYAR (16 events)
in the second 6 months. A limited number of events are
observed during the second, third, and fourth year of follow-up
(3, 2, and 1 event respectively), reducing the IR to around
0.5/100 PYAR. In addition, for the PB group, no new events
were observed in the final year. Of all events in the MB group,
64% were observed in the first year, 29% in the second year,
and the remaining 7% in the successive years.
Regarding the first event of type 1 reaction (Figure 2), the
majority of cases are seen in the MB group. The IR is 23.5/100
PYAR (36 events) in the first 6 months, and decreases rapidly to
9.3/100 PYAR (12 events) in the second 6-month period,
4.2/100 PYAR (9 events) in the second year, and 2.1/100 PYAR
(3 events) in the third year. No new type 1 reactions were seen
during the fourth and fifth years in this group. A small but
constant number of type 1 reactions were observed over all 
5 years in the PB group, with a total of 19 events. Two of these
cases reported after the 36-month follow-up period (not shown
in Figure 2). Five of the 19 cases were redesignated as MB after
initial diagnosis of PB. Of all events in the MB group, 80% were
observed in the first year, 15% in the second year, and the
remaining 5% in the successive years.
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Table 2 Incidence rates and cumulative incidence (%) of first event of nerve function impairment (NFI) and other reactional events amongst
BANDS cohort patients, by diagnostic group—multibacillary (MB) or paucibacillary (PB)
Cumulative 
Leprosy Total no. Cases with Incidence rate incidence at final
group Type of reactional event of cases event (events per 100 PYARa) assessment (%)
MB All NFI 357 121 16.1 34%
Type 1 357 60 8.0 17%
Type 2 357 8 1.1 2%
Silent neuritis 357 101 13.4 28%
NFI at registration 114 78 46.2b 68%
No NFI at registration 243 43 7.4b 18%
PB All NFI 2153 54 0.85 2.5%
Type 1 2153 19 0.30 0.9%
Type 2 2153 n.a. n.a. n.a.
Silent neuritis 2153 50 0.79 2.3%
NFI at registration 149 18 4.42b 12%
No NFI at registration 2004 36 0.61b 1.8%
a Person-years at risk.
b Difference between groups with and without NFI at registration is statistically significant (P < 0.001).
Figure 1 Incidence rate per 100 person-years at risk (PYAR) for first
events of nerve function impairment (NFI) by 6-month periods (first
year) and 12-month period after the first year, according to leprosy
group
Figure 2 Incidence rate per 100 person-years at risk (PYAR) for 
first events of type 1 reaction by 6-month periods (first year) and 
12-month periods after the first year, according to leprosy group
Figure 3 Incidence rate per 100 person-years at risk (PYAR) for 
first events of type 2 reaction by 6-month periods (first year) and 
12-month periods after the first year, according to leprosy group
(multibacillary [MB] patients only)
Finally, in Figure 3, the IR for first event of type 2 reaction 
is shown. These nine events were observed only in the first 
24 months. The IR decreased rapidly from 2.6/100 PYAR 
(4 events) to 1.6/100 PYAR (2 events) in the second 6-month
period, and 0.9/100 PYAR (2 events) in the second year. Of all
type 2 reactions, 75% were observed in the first year and the
remaining 25% in the second year.
Survival curves to first event of nerve function
impairment
Figure 4 shows four survival curves to the first event of NFI
during follow-up. For all patients together, the proportion
surviving without NFI is 94% (Figure 4a). For PB patients this
figure is 98%, which is in sharp contrast to MB patients, of
whom only 67% survive without NFI (Figure 4b). Of all
patients without NFI at registration, 97% survive without
developing NFI during the observation period, while this figure
is 68% of all patients with NFI at registration (Figure 4c).
Finally, Figure 4d shows survival according to diagnostic group
(PB/MB), with and without NFI at registration. The proportion
of PB patients with no NFI at registration surviving without
developing NFI during the observation period is 99%. The
figure for those PB patients with NFI at registration is 92%. In
MB patients with no NFI at registration, the percentage
surviving without NFI during the observation period is 84%. Of
MB patients with NFI at registration, only 36% survived
without developing new NFI during follow-up. In Figures 4b,
4c, and 4d the difference between the curves at end-point are
statistically significant (P-value log rank test < 0.05).
Discussion
The occurrence of NFI and reactions in leprosy at first
examination and during MDT has been comprehensively
reviewed.2,8,9,19 In addition to these studies, this paper presents
information based on an observation period of 5 years, well
beyond the duration of MDT. Data are based on a large pro-
spective cohort of 2664 consecutive new patients in a single
leprosy control project. Nearly 92% of these remained in the
study for the complete follow-up period of 36 months for PB,
and 60 months for MB patients.
The incidence of NFI, type 1, and type 2 reactions is described
in two ways. Firstly, incidence rates per 100 PYAR for the first
event of these outcomes are shown over the total observation
period and according to separate time periods. Secondly,
survival curves are calculated showing the probability of
developing the first event of NFI during the observation period.
The patients were stratified according to leprosy classification
and presence of long-standing NFI at registration. These
variables have been shown to be strong predictors for the
occurrence of NFI during treatment and follow-up.16 Of all
patients who were entered into the BANDS cohort, 175 (6.6%)
developed new NFI after registration. The majority of these
patients (125 or 71.5%) did so in the first year, with nearly half
(83 or 47.4%) developing new NFI in the first 6 months after
registration. In the second year the number with new NFI was
38 (21.7%); in the third year 10 (5.7%); in the fourth year 2
(1.1%); and in the final year nil. The pattern is similar for type
1 and type 2 reactions. Although the proportion of patients
experiencing their first NFI event diminishes with time,
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Figure 4 Survival curves to first event of nerve function impairment (NFI) during follow-up: all cases (Figure 4a); according to
leprosy group (Figure 4b); history of NFI at registration (Figure 4c); and history of NFI at registration by leprosy group (Figure 4d)
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KEY MESSAGES
• Of all 2664 leprosy patients included in the cohort analysis, 175 (6.6%) developed new nerve function impairment
(NFI) after registration.
• Of the 175 patients who developed new NFI, 125 (71.5%) did so in the first year; 38 (21.7%) in the second year;
10 (5.7%) in the third year; 2 (1.1%) in the fourth year; and nil in the final year.
• The percentage of paucibacillary (PB) leprosy patients with no NFI at registration surviving without developing
NFI during the observation period was 99%, and for PB leprosy patients with NFI at registration 92%.
• The percentage of multibacillary (MB) leprosy patients with no NFI at registration surviving without developing
NFI during the observation period was 84%, and for MB leprosy patients with NFI at registration only 36%.
• New episodes of NFI and reactions after registration are common in MB patients.
• Further episodes of NFI in those with long-standing prior impairment at diagnosis is common.
• It is important to continue surveillance for 2 years after registration for NFI in MB patients with long-standing
NFI at registration. Active surveillance beyond 2 years is not indicated.
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